Central nervous system (CNS) disorders are some of the most prevalent yet poorly treated illnesses. Achieving sufficient blood-brain barrier (BBB) penetration is one of the biggest challenges in the development of therapeutics for CNS disorders. For instance, according to an article published by National Center for Biotechnology Information, in January 2005, more than 98% of small molecular drugs and almost 100% of larger molecular drugs are ineffective in treating CNS diseases considering that BBB strictly limits the delivery of therapeutic agents to their target site in the CNS. BBB helps to keep homeostasis in the cerebral microenvironment by controlling exchanges of substances between the CNS and the blood and serves an important function in preventing macromolecules, infectious substances, and potential neurotoxins from entering the brain. CNS disorders are rising due to factors such as aging, stress, and, lifestyle changes.
A limited understanding of the pathophysiology underlies that most of the psychiatric disorders such as schizophrenia, major depressive disorder, or bipolar disorder are only effective in a limited proportion of the patients. Some of the CNS disorders include neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease along with various infectious diseases, psychiatric disorders, mental disorders, trauma, mood disorders, and others.
Market Dynamics
The key players are focusing on various growth strategies such as collaborations and agreements which is expected to drive the market growth during the forecast period. For instance, in July 2021, Eli Lilly and Company, an American pharmaceutical company and Banner Alzheimer's Institute announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab, a biological drug in trial to treat early symptoms of Alzheimer's disease in participants at risk for cognitive and functional decline related to Alzheimer's disease (TRAILBLAZER-ALZ 3). TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer's disease in trial participants.
Key features of the study
• This report provides an in-depth analysis of the global central nervous system disorders therapeutics market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global central nervous system disorders therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global central nervous system disorders therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global central nervous system disorders therapeutics market
Market Segmentation
• By Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
o Neurodegenerative Disorders
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
o Infectious Diseases
o Psychiatric Disorders
o Anxiety Disorders
o Trauma
o Mood Disorders
o Others
• By Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
o Analgesics
o Anti-cholinergic Agents
o Anticonvulsants
o Sedatives and Hypnotics
o Antidepressants
o Antipsychotics
o Others
• By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region Insights (Revenue, USD Mn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
North Africa
Central Africa
South Africa
• Key Players
o Biogen Inc.
o Pfizer Inc.
o Eli Lilly and Company
o Merck & Co., Inc.
o Novartis AG
o AstraZeneca Plc.
o Teva Pharmaceutical Industries Ltd.
o Takeda Pharmaceutical Company Limited
o AbbVie Inc.
o Glaxosmithkline plc.
o Otsuka Pharmaceutical Co., Ltd.
o Reddy's Laboratories Ltd.
o Cipla Inc.
o Lupin Ltd
o Glenmark Pharmaceuticals
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Disease Type
Market Snapshot, By Drug Class
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Opportunity
o Impact Analysis
o PEST Analysis
o Regulatory Scenario
o Market Trends
o Key Developments
o Pipeline Analysis
o Regulatory Scenario
o Epidemiology
o Prescription Pattern and Prescribing Behavior
4. Global Central Nervous System Disorders Therapeutics Market, By Disease Type, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Neurodegenerative Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Alzheimer’s Disease
o Parkinson’s Disease
o Multiple Sclerosis
o Others
o Infectious Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Psychiatric Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Anxiety Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Trauma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Mood Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
5. Global Central Nervous System Disorders Therapeutics Market, By Drug Class, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Analgesics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Anti-cholinergic Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Anticonvulsants
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Sedatives and Hypnotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Antidepressants
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Antipsychotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
6. Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Mn)
7. Global Central Nervous System Disorders Therapeutics Market, By Region, 2021 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 – 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2021 – 2033, (USD Mn)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Biogen Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Merck & Co., Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
AstraZeneca Plc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Takeda Pharmaceutical Company Limited
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
AbbVie Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Glaxosmithkline plc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Otsuka Pharmaceutical Co., Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Reddy's Laboratories Ltd.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Cipla Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Lupin Ltd
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Glenmark Pharmaceuticals
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
o Analyst Views
9. Section
o Research Methodology
o About us
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們